2 results
Approved WMOCompleted
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Approved WMOCompleted
Our main objective is to evaluate and compare appliance of Endobon® Xenograft Granules (Biomet 3i) with an established bovine derived bone mineral for regeneration of intra-bony peri-implantitis defects.